Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 14, 2000

View Archived Issues

KF-20444 has potent immunosuppressive activity

Alexion signs transgenic agreement with Genzyme Transgenics

Ligand sells Marathon assets to CoPharma

Lexicon Genetics and Scripps Institute announce functional genomics agreement

Ares-Serono and Alkermes to collaborate on sustained-release formulations of proteins

INDs filed by Anesta for two OTS products

Access files IND for amlexanox oral rinse

Genset and Whitehead Institute collaborate on obesity and diabetes research

Cephalon compounds enhance spinal cord ChAT activity, inhibit kinase activity

Carbapenems synthesized at Merck active against resistant Gram-positive bacteria

PDH activators with benzenesulfonamide structure designed at AstraZeneca

Vertex continues to pursue therapeutically active p38 MAP kinase inhibitors

Esteve presents new COX-2 inhibitor and pharmacological profile

Selective GABA-A alpha5 receptor inverse agonists useful for cognitive impairment

Schering AG expands its presence in Japan

Novo Nordisk demerger: company names, logos revealed

New twist in the mergers saga: Warner-Lambert pursues discussions with Pfizer

Antex creates new antibiotics to combat antibiotic-resistant bacteria

OrthoLogic initiates phase I/II trial of Chrysalin for accelerated tissue repair

Remaking the pharmaceutical industry: two other heavyweights now in merger discussions

Significant progress made in continuing trials of Oralgen/Oralin

Antiobesity effects of LEP-(116-130) do not involve interaction with leptin receptors

Health Canada grants priority review to Vanlev

Carrington completes enrollment for phase III trial of ulcerative colitis treatment

FDA accepts NDA for new Rapamune formulation

Mechanism of MDR reversal by TER-199 under investigation

AltaRex in-licenses antibody from NIH for AIT platform

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...